Outlook Therapeutics Inc OTLK:NASDAQ

Last Price$1.05NASDAQ Previous Close - Last Trade as of 1:00PM ET 11/25/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$1.05 (9)
Ask (Size)$1.08 (7)
Day Low / HighN/A - N/A
Volume196.2 K
  • Latest Stories
  • Commentary and Analysis
Outlook Therapeutics Awards 1.2 Million Stock Purchase Options to Top Management
5:34PM ET 11/23/2022 MT Newswires

Outlook Therapeutics (OTLK) said its compensation committee granted 1 million options to purchase common stock to Chief Executive C Russell Trenary III....

--BTIG Starts Outlook Therapeutics at Buy With $7 Price Target
10:56AM ET 10/31/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Outlook Therapeutics Says US FDA Accepts Biologics License Application for ONS-5010 as Treatment for Eye Disorder
10:47AM ET 10/28/2022 MT Newswires

Outlook Therapeutics (OTLK) said Friday the US Food and Drug Administration has accepted the drugmaker's biologics license application for ONS-5010m=, an...

Insider Buy: Outlook Therapeutics
4:48PM ET 10/05/2022 MT Newswires

Kurt J Hilzinger, Director, on October 04, 2022, executed a purchase for 111,203 shares in Outlook Therapeutics (OTLK) for $142,512. Following the Form 4...

Outlook Therapeutics Partners With AmerisourceBergen for Potential Launch of ONS-5010 in US
10:25AM ET 9/27/2022 MT Newswires

Outlook Therapeutics (OTLK) has partnered with AmerisourceBergen (ABC) to prepare for the potential commercial launch of ONS-5010/Lytenava in the US, if...

--Chardan Capital Starts Outlook Therapeutics at Buy With $10 Price Target
7:02AM ET 9/13/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Outlook Therapeutics Re-Submits Biologics License Application to FDA for ONS-5010 to Treat Eye Disease; Shares Rise
10:08AM ET 8/30/2022 MT Newswires

Outlook Therapeutics (OTLK) said Tuesday it has re-submitted its biologics license application to the Food and Drug Administration for ONS-5010, an...

Sector Update: Health Care Stocks Struggle Tuesday
4:09PM ET 7/05/2022 MT Newswires

Health care stocks continued to sputter this afternoon, with the NYSE Health Care Index sinking 0.8% and the SPDR Health Care Select Sector ETF (XLV) down...

Sector Update: Health Care Stocks Retreating in Tuesday Trade
1:44PM ET 7/05/2022 MT Newswires

Health care stocks were mostly lower this afternoon, with the NYSE Health Care Index sinking 2.2% and the SPDR Health Care Select Sector ETF (XLV) down...

Outlook Therapeutics Makes Full Cash Pre-Payment of Convertible Promissory Note; Shares Rise Midday
12:29PM ET 7/05/2022 MT Newswires

Outlook Therapeutics (OTLK) said Tuesday that it made a full cash pre-payment of its unsecured convertible promissory note dated Nov. 4, 2020, and that all...